Details of the Drug
General Information of Drug (ID: DMQKMX3)
| Drug Name |
alpha-propyldopacetamide
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
alpha-Propyldopacetamide; 2-(3,4-Dihydroxyphenyl)pentanamide; 154-62-1; a-propyldopacetamide; Dihydroxyphenylvaleramide; EINECS 205-830-9; Benzeneacetamide,3,4-dihydroxy-a-propyl-,(aR)-; Benzeneacetamide,3,4-dihydroxy-a-propyl-,(aS)-; .alpha.-Propyldopacetamide; ACMC-20mn67; ACMC-20mn66; AC1Q5IT3; AC1L2R8E; GTPL5095; CTK8G6411; GDXQWRJYXZXWMT-UHFFFAOYSA-N; MolPort-003-894-618; KUC106729N; 2-(3,4-Dihydroxyphenyl)valeramide; AKOS024285098; a-propyl-3,4-dihydroxyphenyl-acetamide; MCULE-1302132273
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL is unavailable | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 209.24 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.5 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||
References


